FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study †
Titel:
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study †
Auteur:
Iwamoto, S. Takahashi, T. Tamagawa, H. Nakamura, M. Munemoto, Y. Kato, T. Hata, T. Denda, T. Morita, Y. Inukai, M. Kunieda, K. Nagata, N. Kurachi, K. Ina, K. Ooshiro, M. Shimoyama, T. Baba, H. Oba, K. Sakamoto, J. Mishima, H.